U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07645222) titled 'PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC' on June 08.
Brief Summary: This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-20122 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Study Start Date: June 30
Study Type: INTERVENTIONAL
Condition:
Lung Cancer
Intervention:
DRUG: HS-20122+Aumolertinib
EGFR mut NSCLC, receive HS-20122+Aumolertinib
DRUG: HS-20122+Adbrelimab
EGFRwt NSCLC,receive HS-20122+Adbrelimab
DRUG: HS-20122+Adbrelimab+Platinum-based Chemo
EGFR wt NSCLC,receive HS-20122+...